Novo-Nordisk stock heads into the open after a strong 3.5 percent gain
Published on 09/18/2026 at 07:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 17, 2026, Novo-Nordisk stock finished the US session at USD 43.20 on the New York Stock Exchange, up 3.5 percent from the prior trading day. The advance left the shares trading well below some fair value estimates that put intrinsic value above USD 100 per share.
September 17, 2026 in numbers
Novo-Nordisk A/S (ISIN DK0062498333, NYSE: NVO) saw its US-listed shares climb to a closing price of USD 43.20 on September 17, 2026, with an intraday range that included a session high near USD 43.20 and a low that remained above the prior close, according to exchange data. Per NYSE figures, the 3.5 percent daily gain on September 17, 2026 came on elevated trading activity compared with recent sessions, underscoring renewed interest in the stock. The close kept the shares comfortably above their 52-week low while still significantly below their 52-week high, indicating scope for further recovery if positive sentiment persists.
Market commentary pointed to valuation as an important backdrop for the move. As GuruFocus reported on September 17, 2026, one GF Value model put fair value for the shares at USD 104.84 versus a market price in the low USD 40s, implying that the stock remains markedly undervalued despite the latest rally. The same analysis highlighted the company’s dividend profile within that valuation framework, which helped underpin demand for the shares in the latest session.
Events and focus today
Today, September 18, 2026, investors monitor Novo-Nordisk for further communications after the recent valuation-driven move and ongoing interest in the company’s drug portfolio. A Scandinavian market schedule compiled by Placera lists Novo Nordisk among companies with planned information releases around September 18, 2026, suggesting the possibility of new corporate updates later in the day. In addition, broader equity sentiment following the previous session’s gains in healthcare and pharmaceutical names may influence Novo-Nordisk shares into today’s US open, as sector flows and risk appetite continue to shape trading conditions.
